No Detail Found!

De novo design of novel spike glycoprotein inhibitors using e-pharmacophore modeling, molecular hybridization, ADMET, quantum mechanics and molecular dynamics studies for COVID-19

Author(s)
Abdulrahim A Alzain Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira,Gezira,Sudan
Abdalla Ismail Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira,Gezira,Sudan
Mohammed Fadlelmola Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira,Gezira,Sudan
Magdi A Mohamed Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University,Sakaka, Kingdom of,Saudi Arabia
Mohanad Mahjoub Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira,Gezira,Sudan
Alaa A Makki Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira,Gezira,Sudan
Tilal Elsaman Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University,Sakaka, Kingdom of,Saudi Arabia
Abstract
The pandemic COVID-19, caused by SARS-COV-2, has been a global concern and burden since April 2020 due to high contagiousness and pathogenesis. A great effort is being devoted to identify and investigate different druggable targets for SARS-COV-2 drug discovery. At least three targets have been identified among them is the spike glycoprotein which facilitates viral entry by binding to angiotensin converting enzyme (ACE-2 receptor) in host cell. In the current study, different computational tools were used to design potential cell entry inhibitors targeting spike glycoprotein. The essential pharmacophoric features were identified by e-pharmacophore mapping and fragments virtual screening was run using three different libraries. Docking scores were used to select the best fragments which were linked to afford novel molecules. The designed molecules were filtered via molecular docking, MM-GBSA free energy calculation, ADMET, drug-like properties and DFT calculations. Moreover, synthetic feasibility of the best ligands was studied. These ligands would be envisioned as potential leads for SARS-COV-2 cell entry inhibition and could be explored further towards COVID-19 drug discovery and development.
Publication Details
Page(s) 313-321
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: SUP1, Year: 2022

Request the full text from PASTIC

Keywords
Molecular dynamics, FBDD, Spike glycoprotein, pharmacophore mapping and screening, SARS-CoV-2, molecular docking, DFT
References
Agrawal U,Katikireddi SV,McCowan C,Mulholland RH,Azcoaga-Lorenzo A,Amele S,Fagbamigbe AF,Vasileiou E,Grange Z,Shi T .2021 .COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): A prospective cohort study. Lancet Respir. Med, 9(12) : 1439-1449.
Ahsan T,Sajib AA .2021 .Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor. Biochem. Biophys. Rep, 26 : 100982.
Ameen F,Mamidala E,Davella R,Vallala S R .2021 .Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug. J. Infect. Public Health, 14(10) : 1454-1460.
Bassi LL. Hwenda L .2020 .COVID-19: time to plan for prompt universal access to diagnostics and treatments. Lancet Glob. Health, 8(6) : e756-e757.
Bochevarov AD,Harder E,Hughes TF,Greenwood JR,Braden DA,Philipp DM,Rinaldo D,Halls MD,Zhang J,Friesner RA .2013 .Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences. Int. J. Quantum Chem, 113(18) : 2110-2142.
Bowers KJ,Chow DE,Xu H,Dror RO,Eastwood MP,Gregersen BA,Klepeis JL,Kolossvary I,Moraes MA,Sacerdoti FD .2006 .Scalable algorithms for molecular dynamics simulations on commodity clusters. SC'06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, IEEE, : 43.
Cecon E,Burridge M,Cao L,Carter L,Ravichandran R,Dam J,Jockers R .2021 .SARS-COV-2 spike binding to ACE2 in living cells monitored by TRFRET. Cell Chem, 28 : 1-10.
Choudhury C .2021 .Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. J. Biomol. Struct. Dyn., 39(10) : 3733-3746.
Dixon SL,Smondyrev AM,Knoll EH,Rao SN,Shaw DE. Friesner RA .2006 .PHASE: A new engine for pharmacophore perception, 3D QSAR model development and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des, 20(10) : 647-671.
Elbadwi FA,Khairy EA,Alsamani FO,Mahadi MA,Abdalrahman SE,Ahmed ZAM,Elsayed I,Ibraheem W,Alzain AA .2021 .Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studies. Inform. Med, 26 : 100725.
Ertl P and Schuffenhauer A .2009 .Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J. Cheminform., 1(1) : 8.
Fadaka AO,Aruleba RT,Sibuyi NRS,Klein A,Madiehe AM,Meyer M,Biomol M .2020 .Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: A computational-aided approach. , : 1-13.
Friesner RA,Murphy RB,Repasky MP,Frye LL,Greenwood JR,Halgren TA,Sanschagrin PC. Mainz DT .2006 .Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein- ligand complexes. J. Med, 49(21) : 6177-6196.
Giofrè SV,Napoli E,Iraci N,Speciale A,Cimino F,Muscarà C,Molonia MS,Ruberto G,Saija A .2021 .Interaction of selected terpenoids with two SARS-CoV-2 key therapeutic targets: An in silico study through molecular docking and dynamics simulations. Comput. Biol. Med, 134 : 104538.
Gobeil SM,Janowska K,McDowell S,Mansouri K,Parks R,Manne K,Stalls V,Kopp MF,Henderson R,Edwards RJ,Haynes BF,Acharya P .2021 .D614G Mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction. Cell Rep, 34(2) : 108630.
Gupta P,Thomas SE,Zaidan SA,Pasillas MA,CoryWright J,Sebastián-Pérez V,Burgess A,Cattermole E,Meghir C,Abell C,Coyne AG,Jacobs WR,Jr. WR,Blundell TL,Tiwari S,Mendes V .2021 .A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis. Comput. Struct. Biotechnol. J., 19 : 3491-3506.
Hagar M,Ahmed HA,Aljohani G,Alhaddad OA G .2020 .Investigation of some antiviral N-heterocycles as COVID 19 drug: Molecular docking and DFT calculations. Int. J. Mol. Sci, 21(11) : 3922.
Hollingsworth SA,Dror RO .2018 .Molecular dynamics simulation for all. Neuron., 99(6) : 1129-1143.
Jacobson MP,Pincus DL,Rapp CS,Day TJ,Honig B,Shaw DE,Friesner RA .2004 .A hierarchical approach to all‐atom protein loop prediction. Proteins, 55(2) : 351-367.
Kaur SP,Gupta V,Vaccine V .2020 .A comprehensive status report. Virus Res., 288 : 198114.
Konze KD,Bos PH,Dahlgren MK,Leswing K,TubertBrohman I,Bortolato A,Robbason B,Abel R,Bhat S R,Chem R .2019 .Reaction-based enumeration, active learning, and free energy calculations to rapidly explore synthetically tractable chemical space and optimize potency of cyclin-dependent kinase 2 inhibitors. , 59(9) : 3782-3793.
Kyriakidis NC,Lopez-Cortés A,González EV,Grimaldos AB,Prado EO .2021 .SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ. Vaccines, 6(1) : 28.
Lai CC,Shih TP,Ko WC,Tang HJ,Hsueh PR .2020 .Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents, 55(3) : 105924.
Li Q .2020 .Application of fragment-based drug discovery to versatile targets. Front Mol. Biosci, 7 : 180.
Lopez Bernal J,Andrews N,Gower C,Gallagher E,Simmons R,Thelwall S,Stowe J,Tessier E,Groves N,Dabrera G,Myers R,Campbell CNJ,Amirthalingam G,Edmunds M,Zambon M,Brown KE,Hopkins S,Chand M,Ramsay M M .2021 .2 (Delta) variant. N. Engl. J. Med, 385(7) : 585-594.
Massinga Loembé M and Nkengasong JN .2021 .COVID-19 vaccine access in Africa: Global distribution, vaccine platforms and challenges ahead. Immunity, 54(7) : 1353-1362.
Mesa-Vieira C,Botero-Rodríguez F,Padilla-Muñoz A,Franco OH,Gómez-Restrepo C .2021 .The Dark Side of the Moon: Global challenges in the distribution of vaccines and implementation of vaccination plans against COVID-19. , 149 : 37-39.
Meyers J,Fabian B,Brown N B .2021 .De novo molecular design and generative models. Drug Discov. Today, 26(11) : 2707-2715.
Miar M,Shiroudi A,Pourshamsian K,Oliaey AR. Hatamjafari F .2021 .Theoretical investigations on the HOMO-LUMO gap and global reactivity descriptor studies, natural bond orbital, and nucleus-independent chemical shifts analyses of 3-phenylbenzo [d] thiazole2 (3 H)-imine and its para-substituted derivatives: Solvent and substituent effects. J. Chem. Res., 45(1-2) : 147-158.
Mohamed MA,Dirar AI,Elbadawi MA,Osman WJ,Mohammed MS,Hamdoun S MS .2017 .In silico assessment of the druggability of two novel germacranolides isolated from Capparis decidua (Forsk.) as carbonic anhydrase II inhibitors. J. App. Pharm. Sci., 7(1) : 093-097.
Munir MU,Salman S,Ahmed A,Iqbal W,Abbas Bukhari SN,Ahmad N,Ullah MI,Ahmad MM,Elsaman T,Tahir MA .2021 .Diagnosis, summary of essays and evolving approaches. Pak. J. Pharm. Sci., 34(5) : 1813-1820.
Ortega JT,Serrano ML,Pujol FH. Rangel HR .2020 .Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. Excli J., 19 : 410-417.
Rahman S,Montero MTV,Rowe K,Kirton R,Kunik F .2021 .Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: A review of current evidence. Expert. Rev. Clin. Pharmacol, 14(5) : 601-621.
Sakkiah S,Guo W,Pan B,Ji Z,Yavas G,Azevedo M,Hawes J,Patterson TA,Hong H TA .2020 .Elucidating interactions between SARS-CoV-2 trimeric spike protein and ACE2 using homology modeling and molecular dynamics simulations. Front. Chem, 8 : 622632.
Santos LH,Ferreira RS,Caffarena ER .2053 .Integrating molecular docking and molecular dynamics simulations. Methods Mol. Biol, : 13-34.
Sastry GM,Adzhigirey M,Day T,Annabhimoju R,Sherman W .2013 .Protein and ligand preparation: parameters, protocols and influence on virtual screening enrichments. J. Comput. Aided Mol. Des, 27(3) : 221-234.
Tartof SY,Slezak JM,Fischer H JM,Hong V,Ackerson BK,Ranasinghe ON,Frankland TB,Ogun OA,Zamparo JM,Gray S JM .2021 .Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. The Lancet, 398(10309) : 1407-1416.
Toor HG,Banerjee DI,Darji SA,Pharmacol Eur. J. .2021 .Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.. , 890 : 173720.
Walters WP,Murcko M .2020 .Assessing the impact of generative AI on medicinal chemistry. Nat. Biotechnol, 38(2) : 143-145.
Wilson III DM,Deacon AM,Duncton MA,Pellicena P,Georgiadis MM,Yeh AP,Arvai AS,Moiani D,Tainer JA,Das D .2021 .Fragment-and structure-based drug discovery for developing therapeutic agents targeting the DNA damage response. Prog. Biophys. Mol. Biol, 163 : 130-142.
Yu R and Li P .2021 .Screening of potential spike glycoprotein/ACE2 dual antagonists against COVID19 in silico molecular docking. J. Virol. Methods, 301 : 114424.
Zeng MS,Yu WD,Wang HX,Liu JY,Xu PP JY .2021 .A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2). Int. J Biol. Macromol, 183 : 2248-2261.
Zhang Q,Gefter J,Sneddon WB,Mamonova T. Friedman PA .2021 .ACE2 interaction with cytoplasmic PDZ protein enhances SARS-CoV-2 invasion. , 24(7) : 102770.
Zheng Y,Zheng M,Ling X,Liu Y,Xue Y,An L,Gu N,Jin M .2013 .Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazolebenzimidazole derivatives as potent Aurora A/B kinase inhibitors. Bioorg. Med, 23(12) : 3523-3530.
Zoete V,Daina A,Bovigny C,Michielin O C .2016 .SwissSimilarity: A web tool for low to ultra high throughput ligand-based virtual screening. J. Chem, 56(8) : 1399-1404.
0

Citations

0

Downloads

10

Views